Portola Pharmaceuticals (Portola Pharmaceuticals) Cash-to-Debt : 1.02 (As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Portola Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Portola Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2020 was 1.02.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Portola Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2020.

The historical rank and industry rank for Portola Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

PTLA's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.5
* Ranked among companies with meaningful Cash-to-Debt only.

Portola Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Portola Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Portola Pharmaceuticals Cash-to-Debt Chart

Portola Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

6.40

4.42

1.47

1.20

Portola Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Cash-to-Debt	Get a 7-Day Free Trial															1.16	0.94	1.62	1.20	1.02

Competitive Comparison of Portola Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Portola Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Portola Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portola Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Portola Pharmaceuticals's Cash-to-Debt falls into.

Portola Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Portola Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	429.283	/	(23.749	+	332.943)
	=	1.20

Portola Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	362.896	/	(13.839	+	343.692)
	=	1.02

Portola Pharmaceuticals (NAS:PTLA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Portola Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Portola Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Portola Pharmaceuticals (Portola Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portola Pharmaceuticals Inc (NAS:PTLA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 E. Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.portola.com

Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.

Executives

Dennis M Fenton	director
John B Moriarty	officer: EVP, General Counsel	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Hollings Renton	director
David C Stump	director
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Jeffrey W Bird	director	755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Henry Ward Wolff	director	6701 KAISER DRIVE, FREMONT CA 94555
J. Scott Garland	director, officer: President and CEO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Mardi Dier	officer: EVP and CFO	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Rajiv Patni	officer: EVP, CMO	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
John T Curnutte	officer: EVP R&D	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Charles J Homcy	other: Former Director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William Lis	director, officer: Chief Executive Officer	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080